Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience


The conventional approach to treatment of patients with spondyloarthritis (SpA), particularly ankylosing spondylitis (AS), has serious limitations, adding a sense of urgency to the evaluation of new treatments for these rheumatic disorders. Tumour necrosis factor α (TNFα) is a cytokine that has been shown to mediate inflammatory and regulatory activities in SpA and other immune mediated diseases, including other arthritides and inflammatory bowel disease. Positive results have been reported in several international open label and randomised controlled trials of infliximab and etanercept, the two main biological agents targeting TNFα, which have included approximately 300 patients with SpA. Specifically, TNFα-directed therapy resulted in significant improvements in disease activity, function, and quality of life in these patients, most of whom had AS and received infliximab. Preliminary evidence from open label, long term extension trials suggests clinical benefit with continued use. Serious side effects were rare and consistent with experience from patient groups receiving infliximab or etanercept treatment for inflammatory bowel disease or rheumatoid arthritis. Together, these findings herald an age of more effective treatment of patients with AS with anti-TNFα and other emerging biological agents.

Rationale for use of anti-TNFα therapy in AS

Several observations strongly implicate TNFα in the pathogenesis of AS and suggest the therapeutic potential of anti-TNFα agents in this rheumatic disorder. Significantly higher TNFα serum levels have been found in patients with AS than in patients with non-inflammatory back pain, although the cytokine concentration did not correlate with laboratory or clinical measures of disease activity.1 More recently, high amounts of TNFα messenger RNA1 and protein1 were detected in sacroiliac joint biopsy specimens from patients with AS (fig 1). Sacroilitis, like enthesitis, is almost pathognomonic for AS.7

The relationship between SpA and inflammatory bowel disease provides further evidence of a role for TNFα in AS. Microscopic and macroscopic bowel inflammation resembling early Crohn’s disease has been found in 20–60% of patients with spinal and peripheral arthritis in AS and other forms of SpA.8,9 Gut lesions in patients with AS can be clinically silent and are more often chronic than acute, particularly in those with peripheral arthritis. The potential for shared pathogenic processes in inflammatory bowel disease and SpA has been suggested by a study conducted by May et al.,10 who found identical T cell expansions in the colon mucosa and synovial fluid of a patient with enterogenic SpA. Synovial T cell clones were expanded throughout the colon and peripheral blood and, when stimulated in vitro, produced various cytokines, including TNFα. In vitro studies have shown that production of TNFα is increased in the mucosa of patients with Crohn’s disease.11,12 and controlled clinical studies have documented the efficacy of the anti-TNFα monoclonal antibody infliximab.
for both acute and maintenance treatment in this inflammatory bowel disorder.\textsuperscript{19,20} Paradoxically, the anti-TNFα fusion protein etanercept, given at a dose of 25 mg twice weekly, did not effectively induce clinical response in a recently reported placebo controlled trial of patients with active Crohn’s disease.\textsuperscript{26} Whether this is because of the known pharmacological differences between etanercept and infliximab (for example, recognition of membrane bound TNF by infliximab and lymphotixin binding by etanercept) is not known.

In addition, increased levels of TNFα are found in other arthritides, including psoriatic arthritis (PsA)\textsuperscript{17–19} and rheumatoid arthritis (RA).\textsuperscript{2,3} Although RA is certainly pathogenetically different from SpA and the pathogenic processes underlying the development of RA and SpA have not been clearly established, TNFα may have a pivotal role in both types of inflammatory arthritis. Clinical trials testing the anti-TNFα agents infliximab and etanercept have demonstrated their efficacy in PsA\textsuperscript{29–34} and RA,\textsuperscript{26} with evidence of halted or slowed progression of joint damage in RA.\textsuperscript{27,28}

Taken together, these findings provide a strong argument favouring a role for TNFα in AS and suggest that anti-TNFα agents might be effective therapeutic options in this SpA. The latter hypothesis has been further supported by studies of the immunomodulatory effects of these agents in SpA and confirmed by the results of clinical trials in groups with AS.

**IMMUNOMODULATORY EFFECTS OF ANTI-TNFα THERAPY IN AS**

SpA seems to be associated with impairment in the balance of helper T cells subtypes 1 and 2 (Th1 and Th2), demonstrated by reduced T cell production of interleukin 2 (IL2), interferon γ (IFNγ), and TNFα, and increased synthesis of IL10 in the peripheral blood compartment and at the site of the synovial membrane in patients with the disorder.\textsuperscript{29–31} In a study quantifying T cell cytokine production at the single cell level in patients with AS and healthy controls, Rudwaleit \textit{et al} noted a significantly lower percentage of TNFα positive T cells in human leucocyte antigen (HLA)-B27 positive patients with AS and HLA-B27 positive healthy controls compared with HLA-B27 negative healthy controls.\textsuperscript{32–34} HLA-B27 is strongly associated with AS, occurring in approximately 90% of white AS populations.\textsuperscript{35} Interestingly, low secretion of TNFα, but no difference in the secretion of other Th1 or Th2 cytokines, was detected in patients with early reactive arthritis compared with controls and was significantly correlated with a more chronic course of the disease.\textsuperscript{36} HLA-B27 positive patients with reactive arthritis had lower TNFα secretion than HLA-B27 negative patients. The lower TNFα expression at the cellular level may be explained by the occurrence of systemic down regulation, while local concentrations may be high.

An impaired Th1 profile also has been reported in gut lamina propria lymphocytes from patients with SpA.\textsuperscript{37} Van Damme \textit{et al} found lower IFNγ and IL2 production in this lymphocyte compartment and an increased fraction of IL10/CD3/CD8+ cells.\textsuperscript{38} Using the same methodology, these researchers recorded a similar CD3 cytokine profile in patients with Crohn’s disease.\textsuperscript{39} These findings suggest that impaired Th1 capacity plays a part in the pathogenesis of SpA, possibly through failure of effective bacterial elimination at the initiation of the disease, and that gut mucosal lymphocytes also may actively participate in its development. TNFα appears to be abundantly present at the sites of inflammation, making it a legitimate target of biological treatment.

In two open label pilot studies, anti-TNFα therapy has been shown to reverse abnormalities in Th1 cytokine secretion in SpA.\textsuperscript{40} Treatment with three infusions of infliximab in 20 patients with SpA induced a rapid and sustained increase in IFNγ and IL2 levels and a rapid but transient decrease in IL10 levels in patients with high baseline values, resulting in levels similar to those in healthy control patients.\textsuperscript{41} Similarly, in patients with AS treated with infliximab, investigators observed a significant increase in the percentage of CD3+/TNFα and IFNγ producers after treatment.\textsuperscript{42} In contrast, in a German placebo controlled study of anti-TNFα therapy, a clear reduction was found in the percentage of CD4+ and CD8+ T cells producing TNFα and IFNγ after in vitro stimulation.\textsuperscript{43} Additional studies are needed to clarify this issue.

Further insight into the immunomodulatory mechanisms of anti-TNFα therapy in SpA has been provided by the histological analysis of synovial biopsy tissues from eight patients with treatment resistant SpA, including three patients with AS who were treated with infliximab.\textsuperscript{44} At week 12, analysis showed reductions in the synovial layer thickness and CD68+ macrophages in the sublining layer, and endothelial expression of vascular cell adhesion molecule 1, but not in other adhesion molecules (for example, intercellular adhesion molecule 1, platelet endothelial cell adhesion molecule 1, and E-selectin). The number of neutrophils and CD68+ macrophages in the sublining layer also was decreased at week 12, but no change was seen in the overall degree of inflammatory infiltration because of an increase in CD20+ lymphocytes and plasma cells. Surprisingly, some of these effects, including the adhesion molecule expression, T cell infiltration, and B cell infiltration, may conflict with those reported in RA, suggesting that anti-TNFα therapy may have different immunomodulatory mechanisms in SpA and RA.
Anti-TNFα therapy for AS

Several open label and randomised controlled studies have evaluated the efficacy of the anti-TNFα agents infliximab and etanercept on the axial manifestations and peripheral arthritis of AS (table 1).

### Table 1  Clinical studies of anti-TNFα agents in SpA/AS

<table>
<thead>
<tr>
<th>Study</th>
<th>Site design</th>
<th>Study Patients (n)</th>
<th>Age (y)</th>
<th>Disease duration (y)</th>
<th>Dose</th>
<th>Treatment duration</th>
<th>Outcome parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infliximab</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Brandt et al, 2000     | Berlin, Germany OL AS (11) | 36 (mean) | 5 (median) | 5 mg/kg IV at weeks 0, 2, and 6 | 3 mo | • Clinical/functional assessments (e.g., BASDAI, BASFI, BASMI)  
• GQl assessment (SF-36)  
• Inflammatory markers  
• MRI |
| Van den Bosch et al, 2000 | Ghent, Belgium OL SpA (21) [AS (11)] | 49 (median) | 17 (median) | 5 mg/kg IV at weeks 0, 2, and 6 | 84 d, plus 1 y follow up | • Global disease activity assessments  
• Axial assessments (e.g., BASDAI, BASFI, BASMI)  
• Peripheral arthritis assessments (e.g., Tc, SJC) |
| Stone et al, 2001      | Toronto, Canada OL AS (21) | 38 (median) | 9 (median) | 5 mg/kg IV at weeks 0, 2, and 6 | 14 wk | • Clinical/functional assessments (e.g., BASDAI, BASFI)  
• Clinical assessments  
• Inflammatory markers |
| Spanish Spondyloarthritis Study Group, 2002 | Spain OL SpA (26) [AS* (18)] | 44 (mean) | 15 (mean) | 5 mg/kg IV at weeks 0, 2, 6, 14, 22, and 30 | 30 wk | • Clinical/functional assessments (e.g., BASDAI, BASFI, pain VAS)  
• GQl assessment (SF-36)  
• Inflammatory markers |
| Breban et al, 2002     | France OL AS (50) | 36 (mean) | 15 (mean) | 5 mg/kg IV at weeks 0, 2, and 6 | 6 mo | • Global disease activity assessments  
• Clinical/functional assessments (e.g., BASDAI, BASFI, pain VAS)  
• Inflammatory markers |
| Maksymowych et al, 2002 | Canada RCT | 21 (AS) | 42.5 (mean) | 3 mg/kg IV at weeks 0, 2, and 6, then q 2 mo | 52 WK | • Clinical/functional assessments (BASDAI, BASFI, BASGI, BASMI)  
• MRI (6 patients) |
| Braun et al, 2002      | Germany RCT/OL AS (70) | 39 (mean) | 15 (median) | 5 mg/kg IV at weeks 0, 2, and 6, then q 6 wk | 12 wk (RCT) 54 wk (OL) | • Clinical/functional assessments (e.g., BASDAI, BASFI, BASMI, ASAS, pain NRS)  
• GQl assessment (SF-36)  
• Inflammatory markers |
| Van den Bosch et al, 2002 | Belgium RCT/OL SpA (40) [AS (19)] | 47.3 (placebo) 8 (placebo) | 6.5 (infliximab) | 5 mg/kg IV at weeks 0, 2, and 6, then q 6 wk | 12 wk (RCT) 54 wk (OL) | • Global disease activity assessments  
• Clinical/functional assessments (e.g., BASDAI, BASFI, pain VAS)  
• Inflammatory markers |

**EFFECTS OF ANTI-TNFα THERAPY ON SPINAL MANIFESTATIONS AND PERIPHERAL ARTHRITIS IN PATIENTS WITH AS**

In a single centre, open label pilot study conducted in Berlin, Brandt et al showed that infliximab was very effective in controlling disease activity in patients with severe active AS. 

Eleven patients who had AS for a median of five years received infliximab...
three infusions of infliximab, 5 mg/kg, at weeks 0, 2, and 6. DMARDs, other immunosuppressants, and corticosteroids were withdrawn before the administration of infliximab, but NSAIDs were given concomitantly as needed. One patient withdrew from the study because of urticaria. Among the remaining 10 patients, nine improved rapidly and significantly, as measured by the Bath AS Disease Activity Index (BASDAI) (p=0.001). The positive effect occurred as early as one day after the first infusion and, in eight of 10 patients, persisted until week 12 (six weeks after the final infusion). After four weeks, the median improvement in the BASDAI was 70%. Spinal pain, fatigue, and morning stiffness were markedly improved, as well as assessments of peripheral arthritis. In the QoL assessment and measured using the 36 item Short Form Health Survey (SF-36), significant improvement was achieved in median values of six of nine subconcepts. The one year data from this study suggest continuing clinical benefit.iii54

An additional pilot trial with infliximab was performed at a single centre in Belgium in 21 patients with active SpA, including 13 patients with AS (three with only axial disease, seven with associated peripheral arthritis, and one with concomitant PsA).iii54 These patients underwent the same therapeutic regimen as that in the previous German study; they continued receiving stable doses of NSAIDs and corticosteroids during the trial. Rapid and significant improvement in spinal pain was seen in seven of 11 patients after the first infusion (p<0.05), which was sustained after the induction regimen with maintenance infusions every 14 weeks (table 2). At day 84, patients with axial disease had a median improvement of 82% in the BASDAI. Peripheral parameters were assessed in 18 patients who had at least one manifestation of peripheral arthritis or enthesitis. At day 14, morning stiffness and pain were significantly decreased compared with baseline (p<0.001), with significant reductions in tender and swollen joint counts from day 3 onward. Among the 19 patients who completed the one year follow up phase, receiving 5 mg/kg infliximab every 14 weeks, all disease manifestations were significantly improved throughout the period with retreatment.iii55 In an increasing number of patients, symptoms recurred before the subsequent infusion but always disappeared after the re-administration of infliximab. Through the second year of follow up, increasing the dose to 10 mg/kg did not prevent the reappearance of symptoms. However, changing to a regimen of 5 mg/kg every 10 weeks resulted in the maintenance of clinical response.iii56

Stone et al recently reported the findings from an open label, single centre Canadian study of infliximab in 21 patients with active AS in whom conventional treatment had failed.iii57 Patients received the standard induction regimen of infliximab, 5 mg/kg, at weeks 0, 2, and 6. Concomitant drugs, including NSAIDs, methotrexate, sulfasalazine, and corticosteroids, were continued at stable doses throughout the study. Among the 18 patients who were evaluated at week 14, the investigators found a >75% median improvement in functional variables—that is, BASDAI, Bath AS Functional Index (BASFI), Health Assessment Questionnaire, fatigue, and spinal and total body pain. Infliximab was effective in all patients, with the most dramatic response being achieved by patients with shorter disease duration and better baseline clinimetric scores.

Two similar but multicentre pilot studies have been conducted assessing infliximab in patients with active refractory AS in Spain and France. In the Spanish study,iii58 infliximab
5 mg/kg was given to 26 patients with severe SpA at weeks 0, 2, 6, 14, 22, and 30. Eighteen patients with AS were included in this group, all of whom had total ankylosis. Patients were permitted to receive acetaminophen as a rescue analgesic, NSAIDs, and corticosteroids during the study, but not DMARDs. Infliximab treatment resulted in a rapid and significant decrease in clinical disease activity, with clinical response observed after the initial infusion and maintained with subsequent infusions. At weeks 14 and 30, patients demonstrated 57% (p<0.001) and 43% (p<0.001) median improvement in the BASDAI, respectively. Pain, measured using a visual analogue scale (VAS), was reduced by 37% (p<0.001) and 29% (p<0.001) at these times, respectively. Increases were seen in all nine SF-36 measures, reaching statistical significance in three subconcepts (p<0.05). The investigators noted that the clinical responses in these patients with SpA, although more moderate than those previously reported, were none the less remarkable given the severity of their disease (that is, 69% had complete spinal fusion, or “bamboo spine”).

The French experience further supports the dramatic efficacy of this anti-TNFα therapy in axial AS. Breban et al evaluated 50 patients with active, refractory, axial AS but no peripheral arthritis or extra-articular manifestations—for example, uveitis or inflammatory bowel disease, at the time of study entry. NSAIDs were continued at stable doses, but DMARDs were discontinued three months before entry. After treatment with infliximab, patients improved significantly in all measures of disease activity and function at week 8 (p<0.0001), with greater than 70% median improvement in global pain and the BASDAI. Maximal improvement was seen as early as two weeks after the first infusion and within 12 weeks in >80% of patients.

In another recent open trial, 21 consecutive patients with AS (17 men, four women) in Canada, 13 with active peripheral synovitis, mean age 42.5 years (range 24–66), mean disease duration 13.8 years (range 3–26), started intravenous infliximab treatment 3 mg/kg at weeks 0, 2, 6, and every 2 months. Intention to treat analysis was performed with a mean follow up of 48 weeks (range 10–77). Four patients withdrew, two for serious adverse events (septic osteomyelitis and severe hypersensitivity after three and two infusions, respectively). Three patients required an increased dose to 5 mg/kg after 14 weeks. Efficacy data were available on 17 patients at 14 weeks; mean BASDAI improved significantly from baseline (6.2) to 14 weeks (2.8) (p<0.0001), with 10 patients (59%) showing at least 50% improvement (range 0–99.6%). Significant reduction in mean BASFI (43.4%; p<0.001), Bath Ankylosing Spondylitis Global Index (BASGI) (44%; p=0.001), erythrocyte sedimentation rate (ESR) (55%; p<0.001), and C reactive protein (CRP) levels (63.5%; p=0.01) was evident. Complete remission of peripheral joint disease was seen in 5/11 (45%) patients evaluated at 14 weeks, and maximal rate of MRI defined gadolinium augmentation was significantly decreased (p=0.04). Follow up data on eight patients completing one year of treatment showed continued efficacy at a dose of 3 mg/kg every eight weeks. Infliximab appears to be effective and well tolerated for both axial and peripheral joint disease in a subgroup of patients with AS, which still needs to be defined, even at lower doses than those examined to date.

Randomised controlled trials

Two randomised placebo controlled studies evaluating infliximab in patients with AS have been recently published. In a German multicentre study, 70 patients with active AS were randomly allocated to receive either infliximab 5 mg/kg or placebo at weeks 0, 2, and 6; clinical and laboratory assessments were performed at week 12. After the three month controlled phase, an open label extension was conducted, with all patients receiving infliximab 5 mg/kg every six weeks until week 48 and final evaluation being performed at week 54. In the controlled trial, 53% of patients in the infliximab group had a greater than 50% improvement in disease activity at week 12, measured by the BASDAI (fig 2A), compared with 9% in the placebo group (p<0.0001). According to the more rigorous Assessments in Ankylosing Spondylitis (ASAS) Working Group criteria, which require improvement in at least three of four domains (physical function, pain, patient global, and inflammation), with no worsening in the fourth domain, the proportion of patients receiving infliximab who reached greater than 50% improvement approached 50% (fig 2B). In addition, a significantly greater percentage of infliximab treated patients achieved partial remission (20.6%) at weeks 2, 6 and 12, compared with placebo treated patients. Significant improvements were also seen in the infliximab group in function (BASFI; p<0.0001), spinal mobility ( Bath AS Metrology Index (BASMI); p=0.002), and QoL (4/8 SF-36 subconcepts; p<0.0001). Preliminary data from the 54 week extension phase suggest that the clinical benefits associated with short term infliximab treatment are maintained over time with continued treatment. Patients who received infliximab during the controlled study phase had a sustained clinical response up to 54 weeks, whereas those who were switched from placebo to infliximab treatment rapidly achieved similar improvements. The second randomised placebo controlled study, conducted in Belgium, enrolled 40 patients with SpA, including 19 patients with AS. Patients were randomly allocated to receive infliximab 5 mg/kg or placebo, given in the same loading regimen described in the previous study. Concomitant NSAIDs and corticosteroids at stable doses were allowed, but DMARDs

### Table 2 Assessments of baseline and days 14, 42, and 84 after infliximab treatment

| Parameter Baseline Day 14 Day 42 Day 84 |
|-----------------------------------------|--------|--------|--------|
| Global disease activity assessments (n=21) |
| Patient (0–100) | 67 | 23*** | 11*** | 10*** |
| Physician (0–100) | 57 | 23*** | 11*** | 10*** |
| Axial assessments (n=11) |
| Morning stiffness (min) | 90 | 15** | 10** | 5** |
| BASDAI (0–100) | 62.4 | 18.3** | 9.5** | 11.3** |
| BASFI (0–100) | 77.4 | 29.4** | 13.1** | 22.3** |
| Spinal pain (0–3) | 2 | 1 | 0* | 0* |
| Peripheral assessments (n=18) |
| Morning stiffness (min) | 90 | 5*** | 10** | 5*** |
| Tender joint count (0–68) | 6 | 2*** | 0*** | 6*** |
| Swollen joint count (0–68) | 3.5 | 1*** | 0*** | 0*** |

Values are the median; *p<0.05; **p<0.01; ***p<0.001.
were discontinued. The initial three month controlled investigation was followed by a one year open label follow up. In the infliximab treatment group, the investigators observed a significant effect (*p < 0.001 v placebo) on the doctor and patient global assessments of disease activity on a 100 mm VAS, which served as the study’s primary end points, from two weeks and six weeks, respectively, and continuing up to week 12 (fig 3). BASDAI and assessments of peripheral arthritis were significantly improved at 12 weeks in patients receiving infliximab compared with those who received placebo (*p < 0.01 and ‡p = 0.001 v baseline, respectively). Significant clinical improvement in all disease manifestations was maintained with anti-TNFα therapy over the one year follow up period.

Etanercept

Open label study

In a single centre study conducted in the United Kingdom, Marzo-Ortega et al treated 10 patients with refractory SpA, including seven patients with AS. All patients had active axial disease; the majority had peripheral joint disease (n=7) and enthesitis (n=9). Etanercept 25 mg was given subcutaneously twice weekly for six months. Corticosteroids and sulfasalazine were discontinued before study entry, but methotrexate was continued in six patients throughout the study. At week 24, all patients demonstrated significant improvement in standard clinical, function, and QoL assessments (table 3). Improvements of 79% and 38% in BASDAI and BASFI scores, respectively, were reported from baseline to week 24. Enthesitis also resolved or improved in all patients.

Randomised controlled study

In a single centre, randomised, double blind, placebo controlled study conducted in the United States, 40 patients with active AS without complete spinal fusion received either subcutaneous etanercept 25 mg or placebo for four months.* Patients were permitted to continue receiving stable doses of baseline AS drugs, including NSAIDs, corticosteroids, and DMARDs, during the controlled study period. Response was defined as ≥20% improvement in at least three of five primary outcome measures (that is, duration of morning stiffness, degree of nocturnal spinal pain, BASFI, patient global assessment, and swollen joint count), one of which needed to be duration of morning stiffness or degree of nocturnal spinal pain, without worsening in the other measures. Seventy five per cent of patients in the etanercept group achieved a response at day 112, compared with 30% of those in the placebo group (*p=0.01). Response was observed early (by day 28) and maintained over four months, reaching statistical significance at three of the four month points (fig 4). Analysis of the individual primary outcomes showed significant

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>Week 24</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global disease activity assessments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient (0–100)</td>
<td>70</td>
<td>3</td>
<td>0.005</td>
</tr>
<tr>
<td>Physician (0–100)</td>
<td>60.5</td>
<td>3</td>
<td>0.005</td>
</tr>
<tr>
<td>Axial assessments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASDAI (0–10)</td>
<td>6.25</td>
<td>1.3</td>
<td>0.005</td>
</tr>
<tr>
<td>BASFAI (0–10)</td>
<td>7.05</td>
<td>4.35</td>
<td>0.008</td>
</tr>
<tr>
<td>Spinal pain (day; 0–100)</td>
<td>63.5</td>
<td>10</td>
<td>0.008</td>
</tr>
<tr>
<td>Spinal pain (night; 0–100)</td>
<td>71.5</td>
<td>4</td>
<td>0.008</td>
</tr>
<tr>
<td>Peripheral assessments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early morning stiffness (min)</td>
<td>120</td>
<td>2.5</td>
<td>0.008</td>
</tr>
<tr>
<td>Tender joint count (0–68)</td>
<td>6</td>
<td>0</td>
<td>0.046</td>
</tr>
<tr>
<td>Swollen joint count (0–66)</td>
<td>0.5</td>
<td>0</td>
<td>0.043</td>
</tr>
<tr>
<td>Enthesopathy (0–100)</td>
<td>62</td>
<td>3</td>
<td>0.008</td>
</tr>
<tr>
<td>ASQol (0–18)</td>
<td>14</td>
<td>3</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Values are the median.
improvement at four months in the duration of morning stiffness (p<0.001), nocturnal spinal pain (p<0.001), the BASFI (p<0.001), and patient global assessment (p<0.001). Swollen joint counts were lower in etanercept treated patients than in placebo treated patients, but the difference was not statistically significant.

Thirty eight patients from this controlled study were enrolled into a subsequent six month open label extension study of etanercept. Preliminary data demonstrate a durable response in >80% of patients who either continued to receive etanercept or switched from placebo to active treatment. Assessments of all disease manifestations, including function, pain, stiffness, global disease activity, peripheral arthritis, entheses, spinal mobility, and QoL, remained significantly better after six months. During the open label study, patients were permitted to decrease or stop AS drugs. Sixty six per cent of all patients stopped or decreased at least one of their AS treatments by the end of the trial.

EFFECTS OF ANTI-TNF α THERAPY ON SPINAL DISEASE PROGRESSION VISUALISED BY MRI

Detection of disease progression in mild to moderate AS may require as long as two years with conventional imaging by radiograph. However, MRI has been successfully used to visualise acute sacroiliitis, spondylitis, and spondylodiscitis in patients with SpA in recent studies. In contrast with radiographic imaging, which can show the results of inflammation, bony changes, and ankylosis, MRI can detect acute spinal inflammation.

MRI has been used to investigate the impact of anti-TNFα therapy on axial, peripheral, and enthesal disease in patients with AS. Braun et al recently assessed sacroiliac and spinal MRI changes in 20 patients with AS before and after treatment with infliximab. MRI scans after treatment showed resolution of the sacroiliitis and marked improvement in spondylitis, as exemplified by one of the patients (fig 5). A new scoring system was used for spinal MRI (ASspiMRI), which includes an activity score (0–6) that assesses bone marrow oedema by short tau inversion recovery (STIR) and enhancement after gadolinium-diethylenetriamine pentaaetic acid (Gd-DTPA) by scoring 0–3 and, in addition, erosions with signs of active inflammation by scoring 4–6 according to size, while the chronicity score (0–6) assesses sclerosis, erosions (score 1–3), small and big syndesmophytes (score 3–4), partial fusion (score 5), and ankylosis (score 6) by using T1 sequences (minimal score=0, maximal=144 for all three techniques). In correlation with clinical improvement, there was significant regression of spinal inflammation of patients with active AS treated with infliximab 5 mg/kg as assessed by the new MRI scoring system by two independent readers (Braun J, submitted).

In some of the other studies spinal inflammation was also compared before and after treatment with the TNFα blocker. In the study of Stone et al, gadolinium-enhanced MRI imaging showed significant changes in both axial and peripheral joints with infliximab treatment. In the open label trial of etanercept in SpA, scoring was performed on paired MRI scans of enthesal lesions in the lumbar and cervical spine and peripheral joints at baseline and week 24. Thirty eight of 44 lesions (86%) either resolved completely or improved after treatment, and no new lesions developed.

SIDE EFFECTS OF ANTI-TNF α THERAPY

Adverse side effects are the greatest concern with new treatments that are apparently highly effective. There are clearly side effects to be considered in patients treated with anti-TNFα agents. Reports of adverse drug events are reported derived from various sources, including clinical studies, cases reported to regulatory agencies, data reported by drug manufacturers, unpublished cases reported individually or in clusters, and personal experience. Each reporting source has advantages as well as shortcomings. For example, clinical studies are controlled and randomised, but a selected patient group is followed up for a limited period of time. Reports to regulatory agencies are relevant because they reflect how the product is used in practice, but they are uncontrolled and may lead to either underestimation or overestimation of the true
risk and reporting bias. Data from manufacturers are often comprehensive but may be influenced by financial interests. Case reports and anecdotal experiences may or may not be relevant but can incite overreaction because personal experience is involved. Thus, the aggregate of these different sources of information should be considered when drawing valid conclusions about adverse side effects.

In the case of anti-TNFα agents, such conclusions are still difficult because of limited data and experience. However, the early experience with anti-TNFα therapy has identified seven types of adverse events that seem to be of particular concern:

(a) infections, including sepsis and tuberculosis; (b) malignancies such as lymphoma; (c) haematological disorders such as anaemia and pancytopenia; (d) demyelinating disorders and neuropathy; (e) exacerbation of congestive heart failure; (f) production of autoantibodies and autoimmune responses; and (g) infusion or injection and hypersensitivity reactions.

Two cases of tuberculosis were reported in randomised placebo controlled investigations of infliximab in SpA.49,51 One case involved a 65 year old man treated with prednisolone (10 mg/day) for PsA. Because he had no history of pulmonary disease, a purified protein derivative test was not performed. He presented with general malaise, high spiking fever, marked increase in ESR and CRP values, but no respiratory symptoms. Mediastinal adenopathy and nodular lesions in the liver and spleen were evident from a computed tomography (CT) scan. Lymph nodule biopsy after mediastinoscopy showed characteristic lesions of tuberculosis. The overall risk of anti-TNFα therapy, however, appears to be small. Immunocompromised and geriatric patients, and those with identifiable comorbidities, are at increased risk of severe side effects. Patients with cardiac insufficiency should not be treated with anti-TNFα agents. Most adverse events seem to be associated with this drug class rather than with individual agents.

CONCLUSIONS

Recent international experience with the anti-TNFα monoclonal antibody infliximab and TNFα soluble receptor compound etanercept clearly suggests that these biological agents are effective in treating patients with AS. Nearly 300 people with SpA, the majority having AS and receiving infliximab treatment, have been evaluated in controlled and open label studies with consistently positive results. Short term benefits have included significant improvements in disease activity, function, and QoL in treatment resistant AS. Long term investigations are continuing, but early reports indicate maintained response for periods of one to two years. Adverse effects data from the SpA studies of infliximab and etanercept seem to be consistent with those reported previously in studies of RA and Crohn’s disease.

Serious adverse events, including severe infections (for example, tuberculosis), lupus-like disease, and allergy, were rare, but need to be considered. TNFα is a cytokine that has an
essential role in fighting microbes, particularly intracellular bacteria. Although additional information is needed about the possible risk for tuberculosis and other infections with anti-TNFα therapy, recent studies indicate that the treatment does not significantly increase the risk of tuberculosis.

The identification of several new therapeutic targets is crucial for the development of other potentially beneficial biological agents, such as interleukin 1 receptor antagonist. The latter biological treatment has been proved to be effective in RA but has yet to be tested in AS. Discovery of the pathogenic relationship between inflammation of the gut and synovium has resulted in the identification of several new therapeutic targets, including specific adhesion molecules, macrophage subsets, and chemokines. Some of the treatments that are clinically effective in Crohn’s disease result in limited mucosal healing, whereas others, such as azathioprine and infliximab, induce both clinical remission and substantial mucosal healing.

Because the inflammation between the gut and the immune system may play a part in the pathogenesis of AS, treatments that can heal mucosal gut lesions may be of particular interest for the treatment of AS. Although it is too early to speculate about the potential usefulness of other pathogenic targets, it is clear that anti-TNFα therapy represents an essential advance in SpA treatment that has allowed more thorough understanding of disease mechanisms and may lead the way for the introduction of other profoundly effective therapeutic options.

Authors’ affiliations

J Braun, Rheumazentrum Ruhrgebiet, UKBF, Free University, Berlin, Germany
J Sieper, Department of Gastroenterology and Rheumatology, UKBF, Free University, Berlin, Germany
M Breban, Institut de Rhumatologie, Department of Immunology, Hôpital Cochin, Paris, France
E Collantes-Estevez, Department of Rheumatology, Hospital Universitario Reina Sofia, Cordoba, Spain
J Davis, University of California, San Francisco, San Francisco, California, USA
R Inman, University of Toronto, Toronto, Canada
H Marzo-Ortega, Rheumatology Research Unit, The University of Leeds, Leeds, UK
H Mielants, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

REFERENCES


Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience


Ann Rheum Dis 2002 61: iii51-iii60
doi: 10.1136/ard.61.suppl_3.iii51

Updated information and services can be found at:
http://ard.bmj.com/content/61/suppl_3/iii51

These include:

References
This article cites 55 articles, 10 of which you can access for free at:
http://ard.bmj.com/content/61/suppl_3/iii51#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/